Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 20;10(1):235.
doi: 10.1038/s41531-024-00845-5.

Biologically defined neuronal synuclein disease as a tool to advance drug development

Gennaro Pagano  1   2 , Tien Dam  3 , Geoffrey A Kerchner  4 , Wendy R Galpern  5 , Milton Biagioni  6 , Rajesh Karan  7 , Danna Jennings  8 , M Judith Peterschmitt  9 , Tania Nikolcheva  10 , Patrik Brundin  4
Affiliations

Biologically defined neuronal synuclein disease as a tool to advance drug development

Gennaro Pagano et al. NPJ Parkinsons Dis. .

Abstract

In a recent Viewpoint article (JAMA Neurol. 2024;81:789‒90), Okubadejo et al. raised concerns regarding two recent proposals for biological definitions and staging systems for synucleinopathies (the Neuronal Synuclein Disease Integrated Staging System and SynNeurGe system). While acknowledging these concerns, we provide an alternative perspective—that such frameworks represent important steps forward by allowing biologically defined populations to be targeted with precision treatments that can be accurately evaluated using stage-specific outcomes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: G.P., G.A.K., P.B., and T.N. are employees and shareholders of F. Hoffmann-La Roche Ltd. P.B. also has ownership interests in Acousort AB, Enterin Inc, Axial Therapeutics, and Kenai Therapeutics. T.D. is an employee and shareholder of Neumora Therapeutics. W.R.G. is an employee of Janssen Research & Development, LLC, and holds stock and stock options in Johnson & Johnson. M.B. is an employee of UCB. R.K. is an employee and shareholder of Novartis Pharma AG. D.J. is an employee and shareholder of Denali Therapeutics. M.J.P. is an employee of Sanofi and may hold shares and/or stock options in the company.

References

    1. Okubadejo, N. U., Okun, M. S. & Jankovic, J. Tapping the brakes on new Parkinson disease biological staging. JAMA Neurol.81, 789–790 (2024). - PubMed
    1. Simuni, T. et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol.23, 178–190 (2024). - PubMed
    1. Höglinger, G. U. et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol.23, 191–204 (2024). - PubMed
    1. Gibbons, C. H. et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA331, 1298–1306 (2024). - PMC - PubMed
    1. Ji, Z. et al. Global, regional, and national health inequalities of Alzheimer's disease and Parkinson's disease in 204 countries, 1990–2019. Int. J. Equity Health23, 125 (2024). - PMC - PubMed

LinkOut - more resources